Results: Sensitivity, specificity, and accuracy for 18 F-FDG PET/CT (primary and lymph node metastases) at initial staging were 89%, 50%, and 81%. For 18 F-FET PET/CT the numbers were 70%, 90%, and 74%. Sensitivity, specificity, and accuracy for 18 F-FDG PET/CT at follow-up were 71%, 65%, and 67%. For 18 F-FET PET/CT the numbers were 29%, 100%, and 83%.
Introduction

T he clinical value of 2-deoxy-2-[
18 F]fluoro-D-glucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT) in primary staging of head and neck squamous cell carcinoma (HNSCC) is well documented [1] . Unfortunately, 18 F-FDG also accumulates in inflammatory tissue, which may cause false-positive results and therefore the specificity for malignancies is decreased, in particular after treatment by radiotherapy [2] . As a result of this, radiolabelled amino acids were attracting increasing interest in nuclear medicine over the past years. Amino acids are specifically accumulated in malignant cells owing to increased expression of amino acid transporters. In contrast to glucose derivates, the uptake of amino acids in macrophages and other inflammatory cells is absent or at least reduced [3, 4] , therefore the amino acid tracers appear to be more specific for tumor than FDG. Promising results for the detection of HNSCC have been reported using L-methyl-[ 11 C]-methionine [5] and L- [1-(11) C]-tyrosine [3] as a tracer. The drawback is the short physical half-life (20 min) of the 11C label. On the contrary, 18F-labelled amino acid analogues, such as O- (2-[ 18 F]fluoroethyl)-L-tyrosine ( patients with HNSCC the rate of false-positive results by 18 F-FDG PET is considerable. Previous studies describing 18 F-FET as a potential tracer in HNSCC were first evaluating its value for initial staging [6] . According to the disappointing results compared with 18 F-FDG, later studies investigated 18 F-FET in the follow-up setting [7, 8] . The aim of this prospective study was, for the first time, to assess the diagnostic value of 18 F-FET PET/CT in a cohort of patients with advanced HNSCC compared with 18 F-FDG PET/CT at the time of initial staging and following radiochemotherapy in the same patients, resulting in an intra-individual comparison of the two modalities.
Materials and Methods
Patients
A total of 13 patients from the Department of Otorhinolaryngology, Head and Neck Surgery at a tertiary referral center have been enrolled in this prospective study between June 2008 and June 2009. This patient cohort does not represent a consecutive group of all patients diagnosed with a HNSCC within the given time frame, because mainly patients with advanced disease (T3/4, N2/3) were referred to 18 F-FDG PET/CT for search for potential distant metastases. All of the patients were suffering from a previously untreated HNSCC and all of the patients were staged by undergoing panendoscopy, ultrasound-guided fine needle aspiration cytology (USgFNAC) of the neck and biopsy of the primary. It is the institutional policy that all the patients suffering from HNSCC are primarly staged by USgFNAC as a first line examination. In our experience, it is one of the most accurate methods for staging the neck. In ten patients, the primary was located in the oropharynx, whereas two patients were suffering from SCC of the oral cavity, and one patient presented with a poorly differentiated SCC of the nasopharynx. Further tumor characteristics are listed in Table 1 .
Each of the 13 patients was examined with 18 F-FDG PET/CT and 18 F-FET PET/CT, before treatment. The order of the PET/CTs was arbitrary. The interval between the two imaging modalities was not longer than 2 weeks. Ten of those were again scanned 10 weeks after treatment. The initial PET imaging was done before panendoscopy. No therapy between the two imaging modalities was done. In the patients which had a contrast-enhanced CT or MRI before the PET-CT scan, the CT part of the PET-CT scan was done without contrast. Radiochemotherapy consisted of intensity-modulated radiotherapy (IMRT) and simultaneous systemic treatment was performed with cisplatin (40 mg/m 2 per week) or cetuximab (standard dosage). This study was approved by university ethics committee. All subjects gave written informed consent for participation in this prospective study.
Positron Emission Tomography Imaging
For this study, we used a combined PET/CT system (Discovery LS, RX or Discovery STE, GE Health Systems, Milwaukee, WI). This device integrates a PET scanner with a multi-slice helical CT and permits the acquisition of coregistered CT and PET images in the same session. Patients were examined in supine position.
Immediately following the low-dose CT acquisition (FOV 50 cm, auto mA, 120 kV, slice-thickness 3.75 mm, 0.5 s rotation time, standard reconstruction type), 3D-PET emission data were acquired for 1.5 and 2 min/bed position, respectively. The CT data were used for attenuation correction and images were reconstructed using a fully 3D iterative algorithm (VUE Point HD). The CT scan was acquired during breath holding in the normal expiratory position. The PET/CT scans were started 45 min following injection of 350 MBq 18 F-FDG, and, in accordance to a previous report by Pauleit D et al. [7] , 60 min after the application of 250 MBq 18 F-FET. The acquired images were post-processed with a dedicated software (Volume Viewer PET/CT, AW 4.4 workstation, GE Healthcare) providing multiplanar reformatted images of PET alone, CT alone and fused PET/CT with linked cursors. At our institution, blood glucose is checked in every patient before the 18 F-FDG injection. In this study, no patient suffered from hyperglycemia.
Standard of Reference and Data Analysis
The 18 F-FDG-and 18 F-FET PET/CT scans were evaluated by two physicians, board certified in radiology and nuclear medicine and both with years of PET/CT experience. Each read either the 18 F-FET or the 18 F-FDG scan without access to the other scan. The results from panendoscopy and cytological/histological work-up were not available for the nuclear medicine specialists. The primary tumor and suspicious lymph nodes were identified on CT or on the PET scan. The standard of reference was the biopsy of the primary, and the fine needle aspiration cytology of all the suspicious cervical lymph nodes. As all the patients underwent USgFNAC before and after treatment, a false-negative finding in the PET/CT scans is defined as missed lymphatic disease in 18 F-FET or 18 F-FDG in a lesion identified either in only one of them or on the CT and verified as tumor in the USgFNAC. In addition, a clinical follow-up for at least 6 months served as the standard of reference (12/13, 92%). A verified positive lymph node during follow-up, which was not identified in the first session by either modality was labelled false negative. In one case, the patient died 1 month after having started an adequate therapy and therefore a follow-up for 6 months was not possible. The ultrasound-guided fine needle aspiration was always performed by the same specialist with a vast experience regarding this staging method.
In summary, all numbers for sensitivity, specificity, and accuracy are lesion based. Three lesions (two lesions suspicious for a second primary and one lesion suspicious for a distant metastasis) were initially not verified by cytology or histology. In two of these cases, a clinical referral was able to exclude a second primary, and in one patient a follow-up imaging examination 6 months later served as reference. All other patients with suspected distant metastasis or secondary primaries distant from the neck were referred for biopsy/cytology.
The tracer uptake in the lesions for both, the 18 F-FET and the 18 F-FDG scan, was visually graded as none, mild, moderate and strong compared with background tissue. Mild, moderate, or strong uptake was considered suspicious for tumor.
In addition to visual analysis, the uptake of 18 F-FDG and 18 F-FET in the primary tumor was expressed as standardized uptake values (SUV). For this purpose a region of interest (ROI) was placed over the tumor using the image analysis software PMOD (PMOD Technologies Ltd., Zurich, Switzerland). The ROI was placed on the 18 F-FDG or the 18 F-FET scan, depending on where it was best visible. It was then transferred to the other modality after co-registration. To avoid any statistical noise, the mean uptake in the ROI was chosen for reporting.
Results
Between 2008 and 2009, the total number of 13 patients (11 males, two females) was evaluated with 18 F-FDG PET/CT and 18 F-FET PET/CT for a previously untreated advanced HNSCC. The mean age of the patients was 63.3 years (range, 53-80 years), and the mean follow-up period of all patients was 12.7 months (range, 1-22 months). One patient could only be followed by a month because of death. All other patients were followed for at least 6 months. Patient information and tumor characteristics are shown in Table 1 . All patients presented in the advanced stages III and IV (International Union against Cancer (UICC) 1997).
Positron Emission Tomography Imaging
Typical examples of 18 F-FDG and 18 F-FET PET scans are illustrated in Figs. 1 and 2 . Figure 1 demonstrates a patient with moderate to strong 18 F-FDG and 18 F-FET uptake in the primary tumor and the lymph node metastases with higher tumor-to-background ratio in the 18 F-FDG scan. In Fig. 2 , the primary tumor and the nodal disease are clearly visible on the 18 F-FDG scan, whereas all malignant lesions, except the primary, are false negative on the 18 F-FET scan. At initial staging a total of 37 lesions were detected in the 13 patients (13 primaries and 24 lymph nodes). The primary tumor was detected in all patients by 18 F-FDG-and 18 F-FET PET/CT. The 18 F-FDG uptake was rated "strong" in all cases. The rating of the 18 F-FET uptake was "strong" in three patients, "moderate" in two cases and mild in eight patients. At follow-up, 11 patients were available for 18 F-FDG and ten for 18 F-FET imaging. The primary tumor site uptake was rated "none" in all patients by using 18 F-FET, whereas with 18 F-FDG, four primary tumor sites were rated "mild", one "moderate" and six were rated "none".
With regard to lymph nodes suspicious findings on 18 F-FDG PET were found in 12 of the 13 patients (92%). The node uptake was rated "moderate" or "strong". In contrast, only seven (54%) patients had suspicious nodes on 18 F-FET PET, the uptake in which was rated "mild" in six patients and "strong" only in one patient. In summary, the lesion based rate at initial staging for the primaries using Table 2 . The sensitivity to detect malignancy was markedly higher for 
Second Primaries and Distant Metastases
At initial staging, 18 F-FDG PET/CT revealed a total of four lesions suspicious for a second primary (one caecal, one T3 N0 M0  III  2  71  Poorly  50  Oropharynx  T4 N1 M0  IV  3  66  Moderate  50  Oropharynx  T4 N0 M1  IV  4  59  Poorly  80  Oropharynx  T3 N1 M0  III  5  66  Poorly  50  Oral cavity  T4 N1 M0  IV  6  52  Moderate  50  Oral cavity  T4 N2c M0  IV  7  62  Poorly  90  Oropharynx  T2 N2b M1  IV  8  80  Poorly  80  Oropharynx  T4 N2b M0  IV  9  57  Moderate  5  Oropharynx  T3 N0 M0  III  10  66  Moderate  60  Oropharynx  T3 N1 M1  III  11  53  Poorly  25  Nasopharynx  T3 N1 M0  III  12  73  Poorly  70  Oropharynx  T3 N0 M0  III  13 55 Moderate 50 Oropharynx T4 N2c M1 IV nr number, TU tumor, class classification, UICC international union against cancer gastric, one cutaneous, one prostate), and a total of three lesions suspicious for distant metastases (all situated in the lungs). The caecal lesion was confirmed as high-grade dysplasia, and two pulmonary lesions were confirmed as distant disease. In contrast, 18 F-FET PET/CT detected only two additional lesions suspicious for a lung metastasis, of which one was confirmed as distant disease. The other lesions detected by 18 F-FDG PET/CT were not seen on the 18 F-FET PET/CT scan.
At follow-up, 18 F-FDG PET/CT, revealed two additional findings suspicious for lung metastases. One was confirmed histologically, and the second was confirmed radiologically with follow-up scans. 
SUV Values at Initial Staging and after Therapy in the Primary Tumor Site
The results of the ROI analysis are demonstrated in Table 3 . The mean SUV and the percentage reduction after therapy were markedly higher for 18 F-FDG than for 18 F-FET. The average ROI SUV was also correlated with the mitotic index and the grade of differentiation. The 18 F-FDG SUV for the moderately differentiated tumors was 16.8 ± 6.4; whereas, for the poorly differentiated tumors it was 11.5±4.1. However, the difference did not reach statistical significance (student's t test). For 18 F-FET, the corresponding numbers were 4.1±2.3 and 3.3± 1.1, respectively, not reaching statistical significance, neither. Furthermore, no significant correlation was found between the mitotic index and the 18 F-FDG or 18 F-FET uptake. F-FDG PET/CT at initial staging [9] . There is also a role for 18 F-FDG PET/CT in detecting second primaries or distant metastases in patients with advanced HNSCC [10, 11] . A major drawback of 18 F-FDG PET/CT is the relatively low specificity, which leads to a high number of false-positive findings, especially after radiochemotherapy due to the high 18 F-FDG uptake in inflammatory cells, which may be present after radiotherapy. This is reflected in the reduced specificity for 18 F-FDG in our study. Therefore, there is a need for a tracer with higher specificity for tumor tissue. Based on earlier studies g., lymphoma, adenocarcinoma) originating at different sites of the body (colorectal, pancreatic, lung, ovarian, breast, head, and neck) [6] . In line with our study, they found a superior specificity but a lower sensitivity of F-FDG PET. This is in line with our study (Figs. 1 and 2) .
After concluding that the use of 18 F-FET allows a better distinction between tumors and inflammatory tissues in most cases of SCC [6] , Pauleit and his colleagues looked at HNSCC only [7] : the sensitivity of 18 F-FDG PET was 93%, the specificity was 79%, and the accuracy was 83% compared with 18 F-FET PET with a sensitivity of 75%, a specificity of 95%, and an accuracy of 90%. In our study, we found the same pattern, with 18 F-FDG being more sensitive but less specific than 18 F-FET in the investigated tumors. As Pauleit stated a potential benefit for 18 F-FET PET in the follow-up of irradiated patients [7] , Balogova et al. looked also at 12 follow-up patients [8] . As in our study, the good specificity of 18 F-FET was confirmed, but the sensitivity was insufficient. However, they suggested, that in certain cases a wait and see strategy may be chosen for an [7] and Balogova et al. [8] , it is the strength of this study to confirm the previous findings in a more powerful way by F-FET before/after treatment and therefore the response to treatment.
After all, in daily practice of managing patients with HNSCC it is worse missing a true-positive lesion than detecting a false-positive one since suspicious lesions can always be further evaluated by fine needle puncture or biopsy, whereas missed tumors may grow into incurable disease. After having looked at the size of the false negatives, the range of the lesion size was between 1.2 and 3.5 cm. Given the 0.5 cm resolution of the used PET/CT system, the size of the lesion was therefore not a reason for the false-negative lesions revealed by 18 F-FET. In addition, 18 F-FDG PET/CT detected a higher number of second malignancies or distant metastases compared with 18 F-FET PET/CT. In our practice, we will continue to use 18 F-FDG PET/CT for advanced disease routinely, as these additional findings heavily affect the management of the patient. Some question may arise regarding the reliability of sensitivities and specificities presented in this paper, due to the relatively low number of patients. However, the number of lesions used to calculate the figures should be sufficient yield a useful estimate. Furthermore, the numbers are in good agreement with earlier published data [8] .
As mentioned above, there is another argument favouring 18 F-FDG based on our intra-individual analysis: the SUV measurements in the primary tumor were considerably higher for 18 F-FDG leading to a higher tumor-to-background ratio (the SUV values at follow-up represent more or less background), which may partially be responsible for the higher sensitivity. Furthermore, 18 F-FET demonstrated a much smaller post-therapeutic percentage reduction compared with 18 F-FDG, reducing its suitability for the evaluation of a treatment. A limitation of this study is that not all patients received a contrast-enhanced CT at the time of PET scanning. It is therefore possible, that some tumorous lesions may have been missed which would have increased the false-negative number for 18 F-FET and 18 F-FDG. However, given the high sensitivity of 18 F-FDG and the fact that most patients were scanned twice, the number of such missed tumorous lesions can be expected to be small. The 18 F-FDG scan was performed 45 min following injection. Other centers use a 60 min uptake time, which potentially increases the tumor-to-background ratio. However, since the 18 F-FDG uptake in the positive lesions was clearly visible at 45 min, it is unlikely that our results would have changed with a 60 min uptake time.
Conclusion
This study delivers further evidence that 18 F-FET is no substitute for 18 F-FDG in the initial staging or follow-up of patients with HNSCC. Although it is more specific, too many malignant lesions are missed due to its lower sensitivity.
